Intermittent short courses of cyclosporine microemulsion for the long-termmanagement of psoriasis: A 2-year cohort study

Background: Cyclosporine is effective in psoriasis, but long-term continuou s therapy may be limited by renal impairment and hypertension. Intermittent short courses of treatment should minimize side effects and improve the ri sk-benefit ratio. Objective: Our purpose was to assess the long-term efficacy and safety of i ntermittent short courses of the microemulsion formulation of cyclosporine (Neoral) in the management of chronic plaque psoriasis unresponsive to topi cal therapies. Methods: In a multicenter open cohort study, 76 subjects were treated inter mittently over a 2-year period. Patients with chronic plaque psoriasis were treated with cyclosporine until clearance of psoriasis or for a maximum of 12 weeks. Patients were then randomized into two groups. Group A stopped c yclosporine abruptly, whereas group B had the dose reduced by 1 mg/kg per d ay each week until cessation, which was within 4 weeks. On relapsing, patie nts received further courses of cyclosporine. intermittent treatment was co ntinued in this way for 2 years. Results: There was no statistically significant difference in the percentag e of time in remission during the 2-year period between patients randomized to stop cyclosporine abruptly (56.2%) and patients randomized to taper cyc losporine within 4 weeks (61.8%). The mean percentage of time that patients received treatment during the study was 40.5% for randomization group A, 4 6.2% for randomization group B, and 42.8% overall. The median time to relap se was 115.5 days after the first treatment course but became progressively shorter after multiple treatment courses. Mean blood pressure and serum cr eatinine levels did not show any clinically significant changes over time. Conclusions: This study indicates that intermittent short courses of cylclo sporine are effective in patients with moderate to severe psoriasis for up to 2 years while improving the safety profile relative to continuous cyclos porine monotherapy.